IPSC News and Press, Century Therapeutics Inc. From 04/18/22

PHILADELPHIA, April 18, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will present at the vi...

The following slide deck was published by Century Therapeutics, Inc. in conjunction with this event. For further details see: Century Therapeutics (IPSC) presents at 21st Annual Needham Virtual Healthcare Conference - Slideshow

PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, wil...

PHILADELPHIA, March 23, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, wil...

Century Therapeutics press release (NASDAQ:IPSC): FY GAAP EPS of -$2.96 beats by $0.38. Cash, cash equivalents, and marketable securities were $358.8 million as of December 31, 2021, as compared to $76.8 million as of December 31, 2020 For further details see: Century Therapeutics GAAP ...

IND submission for lead program CNTY-101 on track for mid 2022; Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma expected to commence after IND submission Entered into a strategic collaboration with Bristol Myers Squibb to develop iPSC-derived allogeneic ce...

PHILADELPHIA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the senior management team will participate...

Gainers: Biofrontera (NASDAQ:BFRI) +14%. Synaptogenix (NASDAQ:SNPX) +11%. IceCure Medical (NASDAQ:ICCM) +10%. Immunic (NASDAQ:IMUX) +10%. Oncternal Therapeutics (NASDAQ:ONCT) +10%. Losers: Sio Gene Therapies (NASDAQ:SIOX) -19%. Anavex Life Sciences (NASDAQ:A...

Bristol Myers Squibb (NYSE: BMY) has made some big acquisitions in the past, and it's now hinting that more deals could be on the way. The pharmaceutical giant recently announced a smaller licensing agreement with Century Therapeutics (NASDAQ: IPSC) instead of a big acquisit...

Collaboration brings together Century’s industry leading iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development First two programs include a program in acute myeloid leukemia and a p...